Spatial Domains
Dominant neighborhood compartment and purity from Tier 1 domain summaries. Bulk files are centralized on the Download page.
1,501-1,550 of 2,070
Spatial Domains
Dominant neighborhood compartment and purity from Tier 1 domain summaries.
2,069 ready
| Sample | Organ | Disease state | Cells | Dominant compartment ?Largest Tier 1 spatial domain by sample fraction; this is a biological neighborhood label, not a row-count summary. | Domain share | Purity | Diversity |
|---|---|---|---|---|---|---|---|
| NSCLC_38242124__IMC__87_B2,10 | Lung | Primary cancer | 3,801 | Tumor/Malignant | 76.9% | 1.00 | 0.03 |
| NSCLC_38242124__IMC__87_B2,11 | Lung | Primary cancer | 3,550 | Tumor/Malignant | 75.4% | 0.99 | 0.03 |
| NSCLC_38242124__IMC__87_B2,12 | Lung | Primary cancer | 3,636 | Tumor/Malignant | 40.5% | 0.96 | 0.16 |
| NSCLC_38242124__IMC__87_B2,13 | Lung | Primary cancer | 3,196 | Stromal | 88.8% | 0.99 | 0.04 |
| NSCLC_38242124__IMC__87_B2,14 | Lung | Primary cancer | 3,738 | Tumor/Malignant | 87.9% | 0.98 | 0.07 |
| NSCLC_38242124__IMC__87_B2,15 | Lung | Primary cancer | 1,327 | Stromal | 31.7% | 0.67 | 0.74 |
| NSCLC_38242124__IMC__87_B2,16 | Lung | Primary cancer | 2,086 | Tumor/Malignant | 52.1% | 0.96 | 0.13 |
| NSCLC_38242124__IMC__87_B2,17 | Lung | Primary cancer | 2,793 | Stromal | 38.7% | 0.86 | 0.43 |
| NSCLC_38242124__IMC__87_B2,2 | Lung | Primary cancer | 4,972 | Tumor/Malignant | 69.3% | 0.97 | 0.12 |
| NSCLC_38242124__IMC__87_B2,3 | Lung | Primary cancer | 3,223 | Tumor/Malignant | 27.7% | 0.96 | 0.18 |
| NSCLC_38242124__IMC__87_B2,4 | Lung | Primary cancer | 3,763 | Tumor/Malignant | 28.8% | 0.93 | 0.28 |
| NSCLC_38242124__IMC__87_B2,5 | Lung | Primary cancer | 3,386 | Tumor/Malignant | 36.6% | 0.89 | 0.33 |
| NSCLC_38242124__IMC__87_B2,7 | Lung | Primary cancer | 3,292 | Tumor/Malignant | 71.2% | 0.98 | 0.09 |
| NSCLC_38242124__IMC__87_B2,8 | Lung | Primary cancer | 3,497 | Tumor/Malignant | 42.6% | 0.98 | 0.07 |
| NSCLC_38242124__IMC__87_B2,9 | Lung | Primary cancer | 2,804 | Tumor/Malignant | 39.0% | 0.71 | 0.54 |
| NSCLC_38242124__IMC__87_B3,1 | Lung | Primary cancer | 2,960 | Tumor/Malignant | 33.2% | 0.60 | 0.82 |
| NSCLC_38242124__IMC__87_B3,10 | Lung | Primary cancer | 3,144 | Tumor/Malignant | 95.6% | 0.99 | 0.03 |
| NSCLC_38242124__IMC__87_B3,11 | Lung | Primary cancer | 2,659 | Tumor/Malignant | 49.2% | 0.97 | 0.12 |
| NSCLC_38242124__IMC__87_B3,12 | Lung | Primary cancer | 2,159 | Tumor/Malignant | 59.8% | 0.97 | 0.12 |
| NSCLC_38242124__IMC__87_B3,13 | Lung | Primary cancer | 2,467 | Tumor/Malignant | 59.0% | 0.94 | 0.18 |
| NSCLC_38242124__IMC__87_B3,14 | Lung | Primary cancer | 1,960 | Tumor/Malignant | 81.6% | 0.98 | 0.04 |
| NSCLC_38242124__IMC__87_B3,16 | Lung | Primary cancer | 1,779 | Stromal | 40.0% | 0.96 | 0.12 |
| NSCLC_38242124__IMC__87_B3,17 | Lung | Primary cancer | 3,804 | Tumor/Malignant | 41.6% | 0.93 | 0.23 |
| NSCLC_38242124__IMC__87_B3,2 | Lung | Primary cancer | 2,855 | Tumor/Malignant | 50.5% | 0.98 | 0.07 |
| NSCLC_38242124__IMC__87_B3,3 | Lung | Primary cancer | 2,849 | Tumor/Malignant | 57.5% | 0.95 | 0.19 |
| NSCLC_38242124__IMC__87_B3,4 | Lung | Primary cancer | 4,398 | Tumor/Malignant | 74.8% | 0.99 | 0.05 |
| NSCLC_38242124__IMC__87_B3,6 | Lung | Primary cancer | 3,332 | Tumor/Malignant | 77.6% | 1.00 | 0.03 |
| NSCLC_38242124__IMC__87_B3,7 | Lung | Primary cancer | 2,618 | Tumor/Malignant | 37.4% | 0.94 | 0.25 |
| NSCLC_38242124__IMC__87_B3,9 | Lung | Primary cancer | 3,195 | Tumor/Malignant | 71.4% | 0.98 | 0.09 |
| NSCLC_38242124__IMC__87_B4,1 | Lung | Primary cancer | 3,188 | Tumor/Malignant | 54.9% | 0.96 | 0.21 |
| NSCLC_38242124__IMC__87_B4,10 | Lung | Primary cancer | 3,266 | Tumor/Malignant | 89.5% | 0.99 | 0.04 |
| NSCLC_38242124__IMC__87_B4,11 | Lung | Primary cancer | 3,881 | Tumor/Malignant | 42.9% | 0.99 | 0.05 |
| NSCLC_38242124__IMC__87_B4,12 | Lung | Primary cancer | 3,934 | Tumor/Malignant | 56.8% | 0.91 | 0.26 |
| NSCLC_38242124__IMC__87_B4,14 | Lung | Primary cancer | 2,847 | Tumor/Malignant | 70.7% | 0.98 | 0.06 |
| NSCLC_38242124__IMC__87_B4,15 | Lung | Primary cancer | 116 | Immune | 54.3% | 0.84 | 0.41 |
| NSCLC_38242124__IMC__87_B4,16 | Lung | Primary cancer | 328 | Tumor/Malignant | 64.6% | 0.92 | 0.20 |
| NSCLC_38242124__IMC__87_B4,17 | Lung | Primary cancer | 317 | Stromal | 82.6% | 0.50 | 0.60 |
| NSCLC_38242124__IMC__87_B4,2 | Lung | Primary cancer | 3,258 | Tumor/Malignant | 39.1% | 0.95 | 0.22 |
| NSCLC_38242124__IMC__87_B4,3 | Lung | Primary cancer | 127 | Tumor/Malignant | 62.2% | 0.78 | 0.49 |
| NSCLC_38242124__IMC__87_B4,4 | Lung | Primary cancer | 3,650 | Tumor/Malignant | 42.5% | 0.97 | 0.13 |
| NSCLC_38242124__IMC__87_B4,5 | Lung | Primary cancer | 2,604 | Tumor/Malignant | 73.2% | 0.97 | 0.11 |
| NSCLC_38242124__IMC__87_B4,6 | Lung | Primary cancer | 3,412 | Tumor/Malignant | 75.7% | 0.98 | 0.07 |
| NSCLC_38242124__IMC__87_B4,7 | Lung | Primary cancer | 3,084 | Immune | 25.8% | 0.49 | 0.80 |
| NSCLC_38242124__IMC__87_B4,9 | Lung | Primary cancer | 391 | Stromal | 44.0% | 0.40 | 0.92 |
| NSCLC_38242124__IMC__87_B5,10 | Lung | Primary cancer | 415 | Stromal | 52.8% | 0.71 | 0.48 |
| NSCLC_38242124__IMC__87_B5,11 | Lung | Primary cancer | 3,545 | Tumor/Malignant | 37.6% | 0.97 | 0.12 |
| NSCLC_38242124__IMC__87_B5,12 | Lung | Primary cancer | 2,494 | Tumor/Malignant | 81.2% | 0.99 | 0.04 |
| NSCLC_38242124__IMC__87_B5,13 | Lung | Primary cancer | 4,118 | Tumor/Malignant | 27.1% | 0.56 | 0.74 |
| NSCLC_38242124__IMC__87_B5,14 | Lung | Primary cancer | 2,217 | Tumor/Malignant | 58.3% | 0.96 | 0.17 |
| NSCLC_38242124__IMC__87_B5,15 | Lung | Primary cancer | 2,216 | Tumor/Malignant | 27.8% | 0.51 | 0.89 |